000161842 001__ 161842
000161842 005__ 20251017144555.0
000161842 0247_ $$2doi$$a10.1177/17562848251335824
000161842 0248_ $$2sideral$$a144505
000161842 037__ $$aART-2025-144505
000161842 041__ $$aeng
000161842 100__ $$aGonzález Fernández, José
000161842 245__ $$aMASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review
000161842 260__ $$c2025
000161842 5060_ $$aAccess copy available to the general public$$fUnrestricted
000161842 5203_ $$aBackground:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals. Interleukin (IL)-17 and IL-23 inhibitors may have beneficial effects on MASLD by reducing systemic inflammation and improving metabolic parameters.
Objectives:
To assess the effect of IL-17 and IL-23 inhibitors on MASLD and liver fibrosis in patients with psoriasis.
Design:
We performed a systematic review that followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.
Data sources and methods:
A literature search was conducted across four databases: MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials, from database inception to September 27, 2024. Observational studies and clinical trials that reported the presence of MASLD and/or liver fibrosis in patients with psoriasis/psoriatic arthritis treated with IL-17 or IL-23 inhibitors were included. The Newcastle Ottawa Scale (NOS) was used for risk of bias assessment in cohort studies, the Revised Cochrane Risk of Bias Tool (RoB2.0) in randomized controlled trials, and the Risk of Bias in non-randomized studies-of Interventions (ROBINS-I v.2) tool in non-randomized trials.
Results:
Fourteen studies were included: four clinical trials, five retrospective cohort studies, three prospective cohort studies, and two post hoc studies. Two cohort studies and one clinical trial showed a low risk of bias. Both post hoc studies had a high risk of bias. Eleven studies assessed the effect of IL-17 inhibitors on MASLD or liver fibrosis; six reported a neutral effect, while five demonstrated improvements in liver tests. Three studies evaluated IL-23 inhibitors; one showed neutral effects, another reported improvement in fibrosis-4 index (FIB-4) scores at 6 months, and the third was still in the recruitment phase.
Conclusion:
IL-17 and IL-23 inhibitors may provide beneficial effects on MASLD and liver fibrosis in patients with psoriasis. Larger, well-designed studies are needed to confirm these findings.
000161842 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000161842 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000161842 700__ $$aPrieto-Torres, Lucía$$uUniversidad de Zaragoza
000161842 700__ $$0(orcid)0000-0001-8789-6783$$aAra Martín, Mariano$$uUniversidad de Zaragoza
000161842 700__ $$aMartínez-Domínguez, Samuel J.$$uUniversidad de Zaragoza
000161842 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000161842 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000161842 773__ $$g18 (2025), 19$$pTherap. adv. in gastroenterol.$$tTherapeutic Advances in Gastroenterology$$x1756-283X
000161842 8564_ $$s1260440$$uhttps://zaguan.unizar.es/record/161842/files/texto_completo.pdf$$yVersión publicada
000161842 8564_ $$s2667805$$uhttps://zaguan.unizar.es/record/161842/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000161842 909CO $$ooai:zaguan.unizar.es:161842$$particulos$$pdriver
000161842 951__ $$a2025-10-17-14:12:46
000161842 980__ $$aARTICLE